- Home
- ALVO
ALVO
Alvotech
as 03-24-2025 4:00pm EST
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Alvotech ALVO prepares to release earnings report on 26 Mar 2025.
| Founded: | 2013 | Country: | Luxembourg |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 102.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.15 - $14.76 | Next Earning Date: | 03-26-2025 |
| Revenue: | $393,919,000 | Revenue Growth: | 517.92% |
| Revenue Growth (this year): | 399.41% | Revenue Growth (next year): | 41.44% |
Latest Alvotech News
ALVO Breaking Stock News: Dive into ALVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Business Wire
6 days ago
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Simply Wall St.
12 days ago
Exploring 3 High Growth Tech Stocks In The US Market
GlobeNewswire
17 days ago
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
GlobeNewswire
a month ago
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
GlobeNewswire
a month ago
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
GlobeNewswire
a month ago
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
GlobeNewswire
a month ago
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Compare ALVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALVO Alvotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.